** Shares of Lupin slide as much as 3.1%
** Japan's Otsuka appeals US district court's ruling in favour of Lupin's generic version of Otsuka's kidney drug Jynarque
** Citi says appeal could delay Lupin's plan to launch its generic in April 2025
** Adds LUPN's pipeline lacks major products to offset potential decline of Jynarque generic in FY27
** Citi keeps "sell", while avg rating of 30 analysts is "hold", per LSEG data
** LUPN climbs ~69% YTD vs ~37% gain in Nifty pharma index
(Reporting by Yagnoseni Das in Bengaluru)
((Yagnoseni.Das@thomsonreuters.com;))
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Comments